FinTechsDepot FinTechsDepot - Empowering FinTech Futures: Where Knowledge Fuels Innovation.

  • HOME
  • ARTICLES
    • Digital banking
  • RESOURCES
    • Whitepaper
    • Infographics
  • GLOBENEWSWIRE NEWS
  • EVENTS
    • Upcoming conference
    • Past Conference
    • Webinar
  • Contact Us
FinTechsDepot
  • Home
  • Admin
  • Page 27

Author

Admin 422 posts 0 comments

Whitepaper

How to Measure the Financial Impact of Physical Risks

Admin Mar 11, 2025
Physical risks resulting from climate change can be acute (driven by an event such as a flood or storm) or chronic…
Whitepaper

Sage Intacct | Overcoming Financial Growing Pains in Professional Services…

Admin Mar 10, 2025
Overcome Financial Growing Pains to Drive Profitability Growing organizations face common challenges like…
Whitepaper

Maximising Financial Impact : Building the Business Case for Source-to-Pay

Admin Mar 7, 2025
Finance professionals face growing challenges in sourcing, procurement, and accounts payable (AP). Key obstacles…
Whitepaper

How Wealth and Asset management firms thrive with Sage Intacct

Admin Mar 6, 2025
Optimizing Financial Performance in Wealth & Asset Management with Sage Intacct Wealth and asset management…
Featured News

Finance Process Improvement & the Global Process Owner Role

Admin Mar 4, 2025
This webinar, scheduled for October 31, 2024, will provide finance leaders with a comprehensive understanding of…
Whitepaper

The future of financial services: better customer experiences start with…

Admin Mar 3, 2025
Over the last few years, consumers have shown extraordinary resilience through much uncertainty. Many have adapted…
Featured News

How Fintech and AI Have Joined Forces to Improve Back-Office Operations

Admin Feb 28, 2025
The fintech industry is constantly bringing new ideas to the fore that have the potential to take off. While some…
Whitepaper

The Power of Ecosystems for Banking

Admin Feb 27, 2025
The rise of Banking as a Service (BaaS) and real-time payments (RTP) are pushing the era of digitalization to new…
Articles

SIP vs. Mutual Fund: Understanding the Differences

Admin Feb 26, 2025
Introduction Investing is a crucial part of financial planning, and mutual funds are one of the most…
Featured News

World Bank President Ajay Banga Unveils Plans to Address Climate Change and Boost…

Admin Feb 25, 2025
Introduction In a significant step toward tackling global challenges, World Bank President Ajay Banga has…
Older Posts
Newer Posts

    SUBSCRIBE NOW


    Via Email
    Via Telephone


    I Agree. I would like to share my information with FinTechsDepot & their partners so that I can receive relevant information about products, services, & offers.

    RECENT POST

    • Everything You Should Know About Contactless Payments
    • Embedded banking but not as you know it
    • How Smart Money Management and Digital Trends Are Reshaping Wealth in 2026
    • INVESTMENT GUIDE Investing for your future
    • 5 Approaches to Scaling Finance Accuracy with AI

    ARTICLE

    ApolloMD Recognized as One of the Best Places to Work in Healthcare in 2026
    2026-05-14T13:35:31Z
    ATLANTA, May 14, 2026 (GLOBE NEWSWIRE) -- ApolloMD has been selected by Modern Healthcare 2026 Best Places to Work in Healthcare, recognizing healthcare organizations that foster strong workplace culture, support...


    Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
    2026-05-14T13:27:00Z
    Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting...


    TOMI Environmental Solutions, Inc. Announces Second SteraMist Hybrid System Installation Contract with a World-Renowned East Coast Research University
    2026-05-14T13:20:00Z
    FREDERICK, Md., May 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announce that we have been awarded the...


    Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
    2026-05-14T13:15:00Z
    Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner


    Sonablate Launches SONA FUSION Global Registry to Advance Precision Sound Medicine and Define Future Standards in Focal Therapy
    2026-05-14T13:03:00Z
    First multinational initiative dedicated to long-term HIFU outcomes in prostate cancer and BPH aims to help close the evidence gap in incision-free prostate care


    CJ Biomaterials Launches New Home Compostable all-PHA Extrusion Coating Resin for Paper Food Serviceware
    2026-05-14T13:00:00Z
    WOBURN, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- CJ Biomaterials, Inc., a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, has announced the commercial...


    Syneos Health Expands Strategic AI Partnerships to Advance Commercial Precision Performance
    2026-05-14T13:00:00Z
    MORRISVILLE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Syneos Health® today announced new and expanded strategic partnerships that strengthen its cutting-edge, AI ecosystem. These innovative solutions represent best-in-breed technologies that...


    Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
    2026-05-14T12:53:00Z
    Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis


    Administrative Experience Emerges as Key Pressure Point for Self-Funded Plans, Brighton Health Plan Solutions Survey Finds
    2026-05-14T12:45:00Z
    New report shows employee satisfaction remains high, but trust can break down when administrative friction gets in the way


    Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
    2026-05-14T12:45:00Z
    Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R...


    AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
    2026-05-14T12:41:00Z
    Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial


    Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
    2026-05-14T12:40:00Z
    Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep...


    Easy Environmental Solutions & Terreplenish® Show Outstanding Yield Increases & Offer Alternative To Petroleum-Based Fertilizers
    2026-05-14T12:40:00Z
    Terreplenish® leads the way as company responds to worldwide nitrogen shortage


    GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
    2026-05-14T12:35:00Z
    Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used...


    Biogen Completes Acquisition of Apellis Pharmaceuticals
    2026-05-14T12:35:00Z
    CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in...


    Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
    2026-05-14T12:32:00Z
    First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized treatment planning


    20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
    2026-05-14T12:31:00Z
    GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and...


    Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
    2026-05-14T12:30:00Z
    MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management...


    Dogwood Therapeutics Announces First Quarter 2026 Financial Results
    2026-05-14T12:30:00Z
    - Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -


    Biodexa issues letter to Shareholders
    2026-05-14T12:30:00Z
    May 14, 2026


    FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
    2026-05-14T12:30:00Z
    PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U.S. Food and Drug Administration (FDA) has...


    Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
    2026-05-14T12:30:00Z
    IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but...


    GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
    2026-05-14T12:30:00Z
    GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer...


    Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
    2026-05-14T12:30:00Z
    Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY...


    CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale’s Biotech Spinouts
    2026-05-14T12:30:00Z
    New Haven-based biotech venture creation platform focused on launching early-stage therapeutics companies from breakthrough Yale University research


    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
    2026-05-14T12:30:00Z
    NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+...


    MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
    2026-05-14T12:30:00Z
    Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.


    SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
    2026-05-14T12:30:00Z
    Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising.


    Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
    2026-05-14T12:30:00Z
    Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment


    Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
    2026-05-14T12:05:00Z
    ~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion

    Copyright © 2026 | FinTechsDepot | All Rights Reserved |
    Privacy Policy | Unsubscribe
    Sign in

    Welcome, Login to your account.

    Forget password?
    Sign in

    Recover your password.

    A password will be e-mailed to you.